FOR FURTHER INFORMATION CONTACT:

Yvette Waples, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 31, Rm. 2417, Silver Spring, MD 20993–0002, 301– 796–9001, MIDAC@fda.hhs.gov.

SUPPLEMENTARY INFORMATION: Pursuant to 41 CFR 102-3.65 and approval by the Department of Health and Human Services and by the General Services Administration, FDA is announcing the renewal of the Medical Imaging Drugs Advisory Committee (the Committee). The Committee is a discretionary Federal advisory committee established to provide advice to the Commissioner. The Committee advises the Commissioner or designee in discharging responsibilities as they relate to helping to ensure safe and effective drugs for human use and, as required, any other product for which FDA has regulatory responsibility.

The Committee reviews and evaluates data concerning the safety and effectiveness of marketed and investigational human drug products for use in diagnostic and therapeutic procedures using radioactive pharmaceuticals and contrast media used in diagnostic radiology and makes appropriate recommendations to the Commissioner of Food and Drugs.

The Committee shall consist of a core of 12 voting members including the Chair. Members and the Chair are selected by the Commissioner or designee from among authorities knowledgeable in the fields of nuclear medicine, radiology, epidemiology or statistics, and related specialties. Members will be invited to serve for overlapping terms of up to 4 years. Non-Federal members of this committee will serve as Special Government Employees, representatives, or Ex-Officio members. Federal members will serve as Regular Government Employees or Ex-Officios. The core of voting members may include one technically qualified member, selected by the Commissioner or designee, who is

identified with consumer interests and is recommended by either a consortium of consumer-oriented organizations or other interested persons. In addition to the voting members, the Committee may include one non-voting representative member who is identified with industry interests. There may also be an alternate industry representative.

Further information regarding the most recent charter and other information can be found at https://www.fda.gov/advisory-committees/medical-imaging-drugs-advisory-committee/medical-imaging-drugs-advisory-committee-charter or by contacting the Designated Federal Officer (see FOR FURTHER INFORMATION CONTACT). In light of the fact that no change has been made to the committee name or description of duties, no amendment will be made to 21 CFR 14.100.

This notice is issued under the Federal Advisory Committee Act (5 U.S.C. app.). For general information related to FDA advisory committees, please visit us at https://www.fda.gov/AdvisoryCommittees/default.htm.

Dated: June 16, 2023.

Lauren K. Roth,

Associate Commissioner for Policy.
[FR Doc. 2023–13330 Filed 6–22–23; 8:45 am]
BILLING CODE 4164–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Health Resources and Services Administration

Notice of Non-Federal Funds Reported by State/Jurisdiction Awardees on the Maternal, Infant, and Early Childhood Home Visiting Program for the Purposes of Meeting Maintenance of Effort Requirements (2019 and 2021)

AGENCY: Health Resources and Services Administration (HRSA), Department of Health and Human Services.

ACTION: Notice.

SUMMARY: HRSA announces the publication of the amount of non-Federal funds each Maternal, Infant, and Early Childhood Home Visiting Program state/jurisdiction awardee has reported expending for fiscal years (FY) 2019 and 2021 for the purposes of meeting maintenance of effort requirements under this provision.

FOR FURTHER INFORMATION CONTACT: Nate Stritzinger, Policy Analyst, Division of Home Visiting and Early Childhood Systems, Health Resources and Services Administration, 5600 Fishers Lane, Rockville, MD 20857; telephone: (301) 443–8590; email: nstritzinger@hrsa.gov.

SUPPLEMENTARY INFORMATION: The MIECHV Program, authorized by section 511 of the Social Security Act, 42 U.S.C. 711, as amended by The Jackie Walorski Maternal and Child Home Visiting Reauthorization Act of 2022 (Section 6101 of the Consolidated Appropriations Act, 2023 (Pub. L. 117-328)), is administered by HRSA in partnership with the Administration for Children and Families. Under section 511(f)(2) of the Social Security Act (42 U.S.C. 711(f)(2)), HRSA is required to publish the amount of non-federal funds each state/jurisdiction awardee has reported expending to satisfy the maintenance of effort (MOE) requirement for FY 2019 and 2021 no later than June 30, 2023. These amounts are listed in Table 1. For the Secretary to make an award to an eligible state or jurisdiction, that entity must meet the MOE requirement outlined in authorizing statute. To meet this requirement, beginning in FY 2023 the total amount of non-federal funds obligated by the eligible entity in the state or jurisdiction in the fiscal year for a MIECHV Program must not be less than the total amount of non-federal funds reported to have been expended by any eligible entity on evidence-based home visiting and home visiting initiatives for such a program in the state in FY 2019 or 2021, whichever is the lesser.

TABLE 1—MATERNAL, INFANT, AND EARLY CHILDHOOD HOME VISITING PROGRAM: NON-FEDERAL FUNDS REPORTED BY STATE/JURISDICTION TO SATISFY MOE REQUIREMENT FOR FY 2019 AND FY 2021

State/jurisdiction	Awardee name	FY 2019 MOE amt.	FY 2021 MOE amt.	
Alaska	Alaska Department of Health and Social Services	\$0.00	\$0.00	
Alabama	Alabama Department of Early Childhood Education	0.00	0.00	
Arkansas	Arkansas Department of Health	0.00	0.00	
American Samoa	American Samoa—Department of Health	0.00	0.00	
Arizona	Arizona Department of Health Services	0.00	0.00	
California	California Department of Public Health	1,879,834	11,948,600.00	
Colorado	Colorado Department of Human Services	5,521,422.00	5,208,778.00	
Connecticut	Connecticut Office of Early Childhood	10,217,642	10,278,822	
District of Columbia	Government of the District of Columbia	707,808.76	635.825.88	

TABLE 1—MATERNAL, INFANT, AND EARLY CHILDHOOD HOME VISITING PROGRAM: NON-FEDERAL FUNDS REPORTED BY STATE/JURISDICTION TO SATISFY MOE REQUIREMENT FOR FY 2019 AND FY 2021—Continued

State/jurisdiction	Awardee name	FY 2019 MOE amt.	FY 2021 MOE amt.
Delaware	Executive Office of the Governor of Delaware	1,219,950.00	1,704,950.00
Florida	Florida Association of Healthy Start Coalitions, Inc	0.00	0.00
Georgia	Georgia Department of Public Health	0.00	0.00
Guam	Government of Guam—Department of Administration	0.00	0.00
Hawaii	State of Hawaii Department of Public Health	3,000,000.00	2,024,999.98
lowa	Iowa Department of Public Health	734,841.00	734,000.00
Idaho	Idaho Department of Health and Welfare	0.00	0.00
Illinois	Illinois Department of Human Services	15,957,767.10	16,172,116.69
Indiana	Indiana State Department of Health	0.00	0.00
Kansas	Kansas Department of Health and Environment	0.00	0.00
Kentucky	Kentucky Cabinet for Health and Family Services	5,914,517.37	5,302,748.42
Louisiana	Louisiana Department of Health and Hospitals	2,600,000.00	2,600,000.00
Massachusetts	Massachusetts Department of Public Health	0.00	0.00
Maryland	Maryland Department of Health and Mental Hygiene	0.00	0.00
Maine	Maine Department of Health and Human Services	2,000,000.00	2,000,000.00
Michigan	Michigan Department of Health and Human Services	5,282,724.00	5,682,692.00
Minnesota	Minnesota Department of Health	6,386,100.25	14,692,443.38
Missouri	Missouri Department of Elementary and Secondary Education	0.00	0.00
Mariana Islands	Commonwealth Healthcare Corporation	0.00	0.00
Mississippi	Mississippi State Department of Health	0.00	0.00
Montana	Montana Department of Public Health and Human Services	112,255.12	139,171.16
North Carolina	North Carolina Department of Health and Human Services	0.00	0.00
North Dakota	Prevent Child Abuse North Dakota	0.00	0.00
Nebraska	Nebraska Department of Health and Human Services	1,081,807.30	952.193.13
	· ·	0.00	0.00
New Hampshire New Jersey	New Hampshire Department of Health and Human Services New Jersey Department of Health	0.00	0.00
New Mexico	New Mexico Department of Children, Youth and Families	0.00	2,275,378.00
Nevada	Nevada Department of Health and Human Services	0.00	28,000.00
New York	New York Department of Health	2,536,808.19	2,627,455.95
Ohio	Ohio Department of Health	19,392,880.00	
	· ·	, ,	31,407,409.00
Oklahoma	Oklahoma State Department of Health	0.00	
Oregon	Oregon Department of Human Services	0.00	0.00
Pennsylvania	Pennsylvania Department of Human Services	0.00	0.00
Puerto Rico	Puerto Rico Department of Health	0.00	0.00
Rhode IslandSouth Carolina	Rhode Island Department of Health	0.00	0.00
	The Children's Trust Fund of South Carolina	0.00	
South Dakota	South Dakota Department of Health	0.00	203,581.14 345,000.00
Tennessee	Tennessee Department of Health	345,000.00	· '
Texas	Texas Department of Family Protective Services	4,034,177.00	3,753,104.00
Utah	Utah Department of Health	0.00	0.00
Virginia	Virginia Department of Health	0.00	0.00
Virgin Islands	Virgin Islands Department of Health Group	0.00	0.00
Vermont	Vermont Agency of Human Services	0.00	0.00
Washington	Washington State Department of Early Learning	3,709,666.00	5,962,416.00
Wisconsin	Wisconsin Department of Children and Families	985,700.00	1,985,700.00
West Virginia	West Virginia Department of Health and Human Resources	982,065.00	978,076.00
Wyoming	Wyoming Department of Family Services	0.00	0.00

Carole Johnson,

Administrator.

[FR Doc. 2023-13357 Filed 6-22-23; 8:45 am]

BILLING CODE 4165-15-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Center for Scientific Review; Notice of Closed Meetings

Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings. The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: Center for Scientific Review Special Emphasis Panel; PAR Panel: Implementation Research on Noncommunicable Disease Risk Factors Among Low- and Middle-Income Country and Tribal Populations Living in Urban Environments.

Date: July 18–19, 2023.

Time: 9:00 a.m. to 5:00 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).

Contact Person: Lauren Susan Penney, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (301) 496–1968, penneyls@ csr.nih.gov.

Name of Committee: Center for Scientific Review Special Emphasis Panel; Member Conflict: Craniofacial and Skeletal Biology, Diseases and Regeneration. Date: July 19, 2023.